Malvern, United States
Baudax Bio, founded in 2019, is a specialty pharmaceutical company headquartered in the United States. With a mission encapsulated in its slogan, "Advancing Acute Care Therapeutics", the company focuses on the development and commercialization of innovative products specifically for acute care settings.
Their flagship product, ANJESO™, is currently promoted as an option for the management of moderate-to-severe pain in adults, showcasing their commitment to non-opioid therapeutic solutions. The company's pipeline also includes promising early-stage candidates, like novel neuromuscular blocker agents and the proprietary drug Dex-IN, an intranasal formulation with multiple therapeutic effects.
An investment of $1.90M was raised in a Post-IPO Equity round on August 17, 2023, signaling ongoing investor interest and confidence. With a strategy of evaluating acquisition and licensing opportunities, Baudax Bio is well-positioned to expand its impact in the biotechnology and pharmaceutical industries.
